S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
NASDAQ:INSM

Insmed Stock Forecast, Price & News

$25.89
-1.07 (-3.97%)
(As of 12/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$25.67
$27.24
50-Day Range
$25.89
$33.45
52-Week Range
$22.00
$45.44
Volume
754,494 shs
Average Volume
943,590 shs
Market Capitalization
$3.06 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.17
30 days | 90 days | 365 days | Advanced Chart
Receive INSM News and Ratings via Email

Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter.


Insmed logo

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INSM
Employees
373
Year Founded
N/A

Sales & Book Value

Annual Sales
$164.41 million
Book Value
$2.71 per share

Profitability

Net Income
$-294.09 million
Net Margins
-243.96%
Pretax Margin
-244.59%

Debt

Price-To-Earnings

Miscellaneous

Free Float
112,891,000
Market Cap
$3.06 billion
Optionable
Optionable

Company Calendar

Last Earnings
10/28/2021
Today
12/03/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/24/2022

Social Links


MarketRank

Overall MarketRank

2.04 out of 5 stars

Medical Sector

575th out of 1,390 stocks

Pharmaceutical Preparations Industry

269th out of 668 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Insmed (NASDAQ:INSM) Frequently Asked Questions

Is Insmed a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Insmed stock.
View analyst ratings for Insmed
or view top-rated stocks.

How has Insmed's stock been impacted by Coronavirus (COVID-19)?

Insmed's stock was trading at $21.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, INSM shares have increased by 21.8% and is now trading at $25.89.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Insmed?

Insmed saw a drop in short interest in the month of October. As of October 29th, there was short interest totaling 7,460,000 shares, a drop of 18.7% from the October 14th total of 9,180,000 shares. Based on an average daily trading volume, of 808,100 shares, the short-interest ratio is presently 9.2 days.
View Insmed's Short Interest
.

When is Insmed's next earnings date?

Insmed is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Insmed
.

How were Insmed's earnings last quarter?

Insmed Incorporated (NASDAQ:INSM) issued its quarterly earnings results on Thursday, October, 28th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by $0.13. The biopharmaceutical company had revenue of $46.80 million for the quarter, compared to analyst estimates of $49.23 million. Insmed had a negative net margin of 243.96% and a negative trailing twelve-month return on equity of 108.34%. The business's quarterly revenue was up 6.8% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.63) earnings per share.
View Insmed's earnings history
.

What price target have analysts set for INSM?

6 equities research analysts have issued 1 year price targets for Insmed's shares. Their forecasts range from $48.00 to $60.00. On average, they expect Insmed's share price to reach $55.17 in the next year. This suggests a possible upside of 113.1% from the stock's current price.
View analysts' price targets for Insmed
or view top-rated stocks among Wall Street analysts.

Who are Insmed's key executives?

Insmed's management team includes the following people:
  • Mr. William H. Lewis J.D., Pres, CEO & Chairman (Age 50) (LinkedIn Profile)
  • Mr. Paolo Tombesi, Chief Financial Officer (Age 55)
  • Ms. Christine A. Pellizzari J.D., Chief Legal Officer & Corp. Sec. (Age 51)
  • Mr. Roger Adsett, Chief Commercial Officer (Age 50)
  • Dr. Paul D. Streck, Advisor (Age 55)

What is Will Lewis' approval rating as Insmed's CEO?

14 employees have rated Insmed CEO Will Lewis on Glassdoor.com. Will Lewis has an approval rating of 78% among Insmed's employees.

What other stocks do shareholders of Insmed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include Gilead Sciences (gild), AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA) and Geron (GERN).

What is Insmed's stock symbol?

Insmed trades on the NASDAQ under the ticker symbol "INSM."

Who are Insmed's major shareholders?

Insmed's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (6.75%), William Blair Investment Management LLC (4.20%), Point72 Asset Management L.P. (3.03%), Bellevue Group AG (2.86%), Alliancebernstein L.P. (1.87%) and Geode Capital Management LLC (1.70%). Company insiders that own Insmed stock include Alfred Altomari, Christine A Pellizzari, David R Brennan, John Soriano, Melvin Md Sharoky, Orlov S Nicole Schaeffer and William Lewis.
View institutional ownership trends for Insmed
.

Which major investors are selling Insmed stock?

INSM stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Barclays PLC, Ghisallo Capital Management LLC, Granahan Investment Management Inc. MA, Eagle Asset Management Inc., Neuberger Berman Group LLC, Voya Investment Management LLC, and Gyon Technologies Capital Management LP. Company insiders that have sold Insmed company stock in the last year include Alfred Altomari, Christine A Pellizzari, John Soriano, Orlov S Nicole Schaeffer, and William Lewis.
View insider buying and selling activity for Insmed
or view top insider-selling stocks.

Which major investors are buying Insmed stock?

INSM stock was acquired by a variety of institutional investors in the last quarter, including Polar Capital Holdings Plc, Point72 Asset Management L.P., Suvretta Capital Management LLC, Peregrine Capital Management LLC, Bellevue Group AG, Two Sigma Advisers LP, Alliancebernstein L.P., and International Biotechnology Trust PLC.
View insider buying and selling activity for Insmed
or or view top insider-buying stocks.

How do I buy shares of Insmed?

Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Insmed's stock price today?

One share of INSM stock can currently be purchased for approximately $25.89.

How much money does Insmed make?

Insmed has a market capitalization of $3.06 billion and generates $164.41 million in revenue each year. The biopharmaceutical company earns $-294.09 million in net income (profit) each year or ($3.92) on an earnings per share basis.

How many employees does Insmed have?

Insmed employs 373 workers across the globe.

What is Insmed's official website?

The official website for Insmed is www.insmed.com.

Where are Insmed's headquarters?

Insmed is headquartered at 700 US Highway 202/206, Bridgewater NJ, 08807.

How can I contact Insmed?

Insmed's mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900, via email at [email protected], or via fax at 732-438-0381.


This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.